Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Table 5

Adverse reaction of 33 advanced CRC patients treated with regorafenib and toripalimab as third-line or above.

Adverse reaction	Grade (n)				Proportion (%)
	1	2	3	4	Grades1–4	Grade3/4
Fatigue	5	2	0	0	21.21	0
Hypertension	3	1	0	0	12.12	0
Hypothyroidism	7	1	0	0	24.24	0
Hand-foot syndrome	8	2	1	0	33.33	3.03
Leukopenia	5	0	0	0	15.15	0
Platelet count decreased	1	1	0	0	6.06	0
Myocarditis	0	0	0	1	3.03	3.03
Liver dysfunction	7	1	1	0	27.27	3.03
Fever	6	2	0	0	24.24	0
Diarrhea	0	1	0	0	3.03	0